Schwann Cells of the Myelin-forming Phenotype Express Neurofilament Protein NF-M

Bernadette M. Kelly, C. Stewart Gillespie, Diane L. Sherman, and Peter J. Brophy
Department of Biological and Molecular Sciences, University of Stirling, Stirling, Scotland, UK, FK9 4LA

Abstract. Immature Schwann cells of the rat sciatic nerve can differentiate into myelin-forming or non-myelin-forming cells. The factors that influence this divergent development are unknown but certain markers such as galactocerebroside distinguish the two cell populations at an early stage of Schwann cell differentiation. Because myelination requires extensive changes in cell morphology, we have investigated the composition and structure of the Schwann cell cytoskeleton at a time when these cells become committed to myelination. Here we show that Schwann cells express a cytoskeletal protein of Mr 145 before diverging into the myelin-forming path, i.e., before they acquire cell-surface galactocerebroside. The p145 protein has the characteristics of an intermediate filament (IF) protein and immunoelectron microscopy shows that it colocalizes with vimentin, which suggests that these two proteins can coassemble into IFs. Elevated intracellular cAMP levels, which can mimic some of the early effects of axons on Schwann cell differentiation, induced p145 synthesis, therefore, we conclude that myelin-forming Schwann cells express this protein at a very early stage in their development. Immunological comparisons with other IF proteins revealed a close similarity between p145 and the neurofilament protein NF-M; the identification of p145 as NF-M was confirmed by isolating and sequencing a full-length clone from a Schwann cell cDNA library. These data demonstrate that Schwann cells remodel their IFs by expressing NF-M before acquiring the myelin-forming phenotype and that IF proteins of the neurofilament-type are not restricted to neurons in the vertebrate nervous system.

Keywords: Schwann cell, myelin, neurofilament, intermediate filament, cAMP, axon.
Immunoblot of cytoskeleton (C) and soluble (S) fractions of Schwann cells (80 μg protein) from 5-d rat sciatic nerves as described in Materials and Methods. (1) Proteins stained with Amido Black; (2) immunoblot with antivimentin; (3) immunoblot with anti-p145. Both vimentin and p145 were exclusively associated with the Schwann cell cytoskeleton and their respective antibodies were specific.

Figure 1. Immunoblot of cytoskeleton (C) and soluble (S) fractions of Schwann cells (80 μg protein) from 5-d rat sciatic nerves as described in Materials and Methods. (1) Proteins stained with Amido Black; (2) immunoblot with antivimentin; (3) immunoblot with anti-p145. Both vimentin and p145 were exclusively associated with the Schwann cell cytoskeleton and their respective antibodies were specific.

and NF-H of apparent molecular masses 68, 150, and 200 kD, respectively, and α-internexin), type V (nuclear lamins), and type VI (nestin) (Lendahl et al., 1990; Steinert and Liem, 1990; Chin et al., 1991). Since IF proteins are often specifically expressed in particular cell types, they have been used as differentiation markers and as such are useful tools in the study of cell differentiation as well as in tumour identification (Osborn and Weber, 1983).

All IF proteins share common structural features: they are all rod-shaped and have a large, highly conserved central α-helical core domain of ~310 residues which is flanked by two nonhelical terminal domains of variable length and sequence at the amino- and carboxy-terminal regions (Weber et al., 1983; Monteiro and Cleveland, 1989). Despite extensive knowledge of their amino acid and cDNA sequences, the physiological function of most IF proteins remains elusive. Their linkage to both nucleus and plasma membrane (Georgatos et al., 1987) suggests a general role in the spatial organization of the cytoplasm; alternatively, IFs may be involved either in the transport of macromolecules between the nucleoplasmic and cytoplasmic compartments or in the transduction of information from the cell periphery to the nucleus.

The Journal of Cell Biology, Volume 118, 1992 398

Figure 2. Immunofluorescence localization of p145 in Schwann cell cytoskeletons. Cells were grown on poly-D-lysine-coated plastic for 24 h before extraction. Cytoskeletons were viewed with (A) phase-contrast optics and (B) rhodamine optics to visualize p145. Note the filamentous staining in the lower cell. Bar, 10 μm.
vimentin and is inducible in culture by cAMP analogues. Immunological analysis suggested that pl45 might be identical to the neurofilament protein NF-M, and this hypothesis was confirmed by cDNA cloning.

Materials and Methods

Schwann Cell Cultures

Sciatic nerves from 1-5-d-old embryonic rats and pups were dissected and dissociated according to the method of Brockes et al. (1979) and the cells were seeded on either 13-mm glass coverslips (BDH, Glasgow, Scotland) or plastic 35-mm dishes (Costar Data Packaging Corp., Cambridge, MA) that had been coated with 100 μg/ml poly-o-lysine (Sigma Chemical Co., St. Louis, MO). Cultures were maintained in OptiMEM (Gibco-BRL, Grand Island, NY) containing 10% FCS (Flow Laboratories, Inc., McLean, VA).

Cell Culture in the Presence of cAMP Analogues

To examine the effects of raised intracellular cAMP levels in Schwann cells, cultures from sciatic nerves of 5-d rat pups were grown for 24 h in OptiMEM containing 10% FCS. The cells were rinsed three times with OptiMEM and then refed in medium containing 5 × 10⁻⁴ M N°, 2'-O-dibutyryl adenosine 3':5'-cyclic monophosphate (db-cAMP) (Sigma Chemical Co.) for 48 h in the presence or absence of FCS with media changes every 24 h. Control cultures were refed with fresh OptiMEM containing 10% FCS every 24 h.

Figure 3. Double-label immunofluorescence localization of pl45 and vimentin in Schwann cell cultures treated with colchicine. Cells were viewed before colchicine by (A) phase contrast, (B) rhodamine optics for pl45, and (C) fluorescein optics for vimentin. Note that the fibroblast has vimentin but does not contain pl45. Colchicine-treated cells are shown by (D) phase-contrast optics, (E) rhodamine optics for pl45, and (F) fluorescein optics for vimentin. Both pl45 and vimentin have retracted to a perinuclear location. Bar, 10 μm.
Figure 4. Immunoelectron localization of p145 and vimentin in Schwann cells. Cytoskeletons were immunostained with p145 antibody and vimentin mAb and then reacted with secondary antibodies that were labeled with colloidal gold particles. IFs were clearly immunostained for both p145 (10 nm gold) and vimentin (5 nm gold) (A and B). Schwann cell IFs composed only of vimentin which were not labeled with anti-p145 are shown in C. Bars, 0.1 μm.

In experiments designed to induce expression of Po, we used a slight modification of the protocol of Morgan et al. (1991). Briefly, after cell culture for 24 h in Optimem containing 10% FCS, 10^{-5} M cytosine arabinoside (Sigma Chemical Co.) was added for 48 h after which time cultures were returned to Optimem containing 10% FCS for a further 24 h. On the fifth day, cAMP analogues db-cAMP and 8-bromoadenosine-cAMP (Sigma Chemical Co.) each at 5 \times 10^{-4} M were added to Optimem containing 2% FCS. On the sixth day, medium was replenished, but the concentration of each cAMP analogue was reduced to 5 \times 10^{-5} M. After a further 24 h, the medium was replaced by serum-free Optimem containing the cAMP analogues. Finally, on the eighth day of culture, cells were processed for indirect immunofluorescence. Control cultures were maintained throughout in Optimem containing 10% FCS and were refed every 24 h.

Preparation of Cytoskeleton Fractions from Schwann Cells

Cell cultures were extracted at room temperature for 3 min with the extraction buffer described by Wilson and Brophy (1989) (10 mM Pipes, pH 6.9, 50 mM KCl, 2 mM EGTA, 1 mM MgCl_2, 2 M glycerol, 10 μg/ml leupeptin (Sigma Chemical Co.), and 10 μg/ml antipain (Sigma Chemical Co.), containing 0.5% (vol/vol) Triton X-100). The cytoskeletons were then...
scraped off with a rubber policeman and sedimented by centrifugation at 14,000 g for 10 min. After labeling, cells were rinsed extensively with Optimem before extraction with the buffer containing Triton X-100. Cytoskeleton fractions were solubilized in 2% SDS with 1 mM DTT and then diluted with 4 vol of solution A (50 mM Tris-HCl, pH 7.4, 2.5% [vol/vol] Triton X-100, 150 mM NaCl, 4 mM EDTA containing 1 mM Na-p-Phosyl-l-lysine chloromethyl ketone [Sigma Chemical Co.], and 10 μg/ml leupeptin [Sigma Chemical Co.]). The solubilized samples were preclarified with protein A agarose (Sigma Chemical Co.) in solution A. Each sample containing 0.8 × 10^6 of TCA-precipitable cpm was incubated with a nonimmune serum (2 μl), affinity-purified pl45 antibody (150 μl), or rabbit antitoxine vimentin (2 μl) for 90 min at room temperature followed by protein A agarose for 60 min. Immune complexes were centrifuged at 13,000 g for 5 min and washed six times with solution A containing 0.1% SDS and finally with solution A without detergent. The samples were solubilized and electrophoresed on 5-17% gradient polyacrylamide gels using the buffer system of Laemmli (1970). Gels were stained with 0.2% PAGE Blue 83 (BDH), destained, incubated with anti-p145. The separated proteins were then electro-transferred to nitrocellulose according to the method of Towbin et al. (1979). The nitrocellulose was blocked by incubation for 3 h with 0.2% (wt/vol) gelatin in PBS containing 0.1% (vol/vol) Triton X-100. Proteins were detected by incubation with appropriately diluted primary antibodies in blocking buffer followed by goat anti-rabbit IgG-HRP conjugate (North East Biochemicals, Uxbridge, England). After washing three times with blocking buffer and once with PBS, immunoreactive proteins were detected using 3,3′-DAB HCl and H2O2 (Sigma Chemical Co.) as substrates in 50 mM Tris-HCl, pH 7.4. The peroxidase reaction was terminated with 2% SDS.

**Antibodies**

Gifts of the following antibodies are gratefully acknowledged. They were used at the indicated dilutions for immunofluorescence and they were diluted a further 10-fold for immunoblotting, rabbit anti-S100 (J. E. Hessketh, Rowett Research Institute, Aberdeen, Scotland) (1:5000); rabbit antivimentin (R. O. Hynes, M.I.T., Cambridge, MA) (1:200); rabbit anti-Po (D. R. Colman, Columbia University, New York) (1:200); affinity-purified pl45 antibody (AII) (1:200); rabbit anti-NF-M is immunologically related to pl45. Schwann cells from 5-d rat sciatic nerve were cultured for 16 h, solubilized in SDS-PAGE sample buffer, and analyzed by immunoblotting. Both AII pl45 (A) and AII (B) confirming that pl45 contained NF-M sequences. The low Mr bands detected by AII in lanes 1 and 2 are presumably proteolytic breakdown products. (b) NF-M is immunologically related to pl45. Schwann cells from 5-d rat sciatic nerve were cultured for 16 h, solubilized in SDS-PAGE sample buffer, and analyzed by immunoblotting. Both AII (lane 2) and Dahl’s rabbit anti-NF-triple antibody (lane 3) recognize a protein with the same Mr, as pl45, which is shown in lane 1 stained with anti-pl45. A western blot analysis was performed to confirm the presence of NF-M in the samples. Immunoprecipitation

Schwann cells from the sciatic nerves of 5-d-old rat pups were grown for 24 h in Optimem containing 10% FCS, rinsed four times in Optimem, and labeled in Optimem containing 10^4 M db-cAMP and [35S]methionine (1 μCi/ml) (ICN Biochemicals, Buckinghamshire, England) for 24 h at 37°C. After labeling, cells were rinsed extensively with Optimem before extraction with the buffer containing Triton X-100. Cytoskeleton fractions were solubilized in 2% SDS with 1 mM DTT and then diluted with 4 vol of solution A (50 mM Tris-HCl, pH 7.4, 2.5% [vol/vol] Triton X-100, 150 mM NaCl, 4 mM EDTA containing 1 mM Na-p-Phosyl-l-lysine chloromethyl ketone [Sigma Chemical Co.], and 10 μg/ml leupeptin [Sigma Chemical Co.]). The solubilized samples were preclarified with protein A agarose (Sigma Chemical Co.) in solution A. Each sample containing 0.8 × 10^6 of TCA-precipitable cpm was incubated with a nonimmune serum (2 μl), affinity-purified pl45 antibody (150 μl), or rabbit antitoxine vimentin (2 μl) for 90 min at room temperature followed by protein A agarose for 60 min. Immune complexes were centrifuged at 13,000 g for 5 min and washed six times with solution A containing 0.1% SDS and finally with solution A without detergent. The samples were solubilized and electrophoresed on 5-17% gradient polyacrylamide gels using the buffer system of Laemmli (1970). Gels were stained with 0.2% PAGE Blue 83 (BDH), destained, incubated for 30 min in Amplify (Amersham Corp., Buckinghamshire, England), and dried. The dried gel was exposed to X-ray film (Konica, Stirling, Scotland) at −70°C and the autoradiograph was developed using Kodak X-ray developer and fixer solutions.

**Indirect Immunofluorescence**

When used on living cells, antibodies were diluted in PBS containing 2% goat serum (Scottish Antibody Production Unit, Carluke, Lanarkshire, Scotland) before fixation. Otherwise, cells were first fixed in 3.7% (vol/vol) paraformaldehyde (Ted Pella) and quenched with 0.1 M glycine in PBS. To detect intracellular antigens, fixed cells were permeabilized with 0.1% (vol/vol) Triton X-100 in PBS for 5 min. For GFAP immunocytochemistry, cells were fixed in ethanol-acetic acid (95:5) for 10 min at −20°C. Fixed cells were blocked with 0.2% (wt/vol) gelatin in PBS. Appropriately diluted antibodies in PBS/gelatin were incubated for 60 min with permeabilized cells and fixed cytoskeletons. The cells were washed and then stained for 30 min with fluorescent-labeled anti-mouse and rhodamine-labeled anti-rabbit IgG (North East Biochemical Laboratories, Uxbridge, England). Each dilution was tested 5-fold with blocking buffer containing 10% goat serum. Coverslips were washed several times with blocking buffer and finally with PBS and then mounted on glass slides using 90 (vol/vol) glycerol, 10% (vol/vol) PBS, 0.1% (vol/vol) 1-phenylendiamine (Alcian Blue Chemical Company, Dorset, England). Fluorescence was viewed using 40× or 63× objectives on a Zeiss microscope equipped with phase-contrast and epifluorescence optics. Kodak T-Max (400 ASA) film was used for all photomicrography. All quoted errors in cell counts are SEMs.

**Electron Microscopy**

Schwann cells cultured on aclar discs (Allied Chem. Corp., Waltham, MA) were extracted to yield cytoskeletons which were then fixed for 30 min in 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. After quenching in 100 mM ammonium chloride, nonspecific protein binding sites on cytoskeletons were blocked with 0.3% (wt/vol) BSA, 0.5% (vol/vol) fish albumin. Schwann cells were then fixed for 90 min in 2% glutaraldehyde in PBS, pH 7.4, rinsed four times in PBS, and post-fixed in 1% osmium tetroxide for 1 h. After washing with PBS, the samples were dehydrated through a graded series of ethanol solutions and embedded in Spurr’s medium. Ultrathin sections were cut with a diamond knife and stained with uranyl acetate and lead citrate. The sections were viewed with a Hitachi H-600 electron microscope at an accelerating voltage of 75 kV.
gelatin (Sigma Chemical Co.), in 20 mM Tris containing 200 mM NaCl, pH 7.4. Primary antibodies were diluted with blocking buffer and incubated for 2 h with cytoskeletons in a humid chamber at room temperature. After washing with blocking buffer, incubations with gold-labeled secondary antibodies were carried out at room temperature for 2 h in a humid chamber. The goat anti-rabbit IgG-10-nm gold (Jackson, Olen, Belgium) and 5-nm gold-labeled goat anti-mouse IgG (Amersham Corp.) antibodies were each diluted 20-fold in blocking buffer. After washing in Tris/NaCl and 0.1 M sodium cacodylate buffer, pH 7.4, samples were fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate for 30 min at room temperature and left overnight in the same buffer. Samples were postfixed with 1% OsO4 in 1% potassium ferrocyanide for 30 min at room temperature and embedded in Epon (Taab). Samples were dehydrated in a graded ethanol series: 50%-5 min, 70%-5 min, 90%-5 min, absolute-10 min (twice), absolute-5 min. The infiltration protocol was Epon in ethanol (1:1) for 1 h at room temperature. Epon, two changes during the next 12 h followed by embedding in fresh Epon and polymerization at 60°C for 12-24 h. Pale-gold sections were cut on an LKB III ultra microtome and sections were viewed on a Jeol 100 CX transmission electron microscope.

**Isolation and Characterization of cDNA clones from Rat Sciatic Nerve and Schwann Cell cDNA Libraries**

Total RNA was extracted from P10 rat sciatic nerve and from cAMP-induced P4 rat Schwann cells with RNazol B (Biogenesis, Bournemouth, England) following the manufacturer's instructions, following which poly-(A)+ RNA was isolated (Aviv and Leder, 1972). For the sciatic nerve cDNA library, first and second strand synthesis was carried out by standard methods (Maniatis et al., 1989). After size fractionation on a Sepharose CL-4B (Pharmacia Fine Chemicals, Piscataway, NJ) column, EcoRI-linkered cDNA was ligated to AgtI1 arms (Promega Biotech, Madison, WI) and packaged using Gigapack Gold (Stratagene, Cambridge, England). The Schwann cell library was constructed unidirectionally in SalI/Nod double-digested Agt22A (Gibco BRL) following the manufacturer's instructions. Affinity-purified anti-p145 antibodies were used to screen 5.0 x 10^5 and 2.5 x 10^6 recombinants in the sciatic nerve and Schwann cell libraries, respectively (Young and Davis, 1983), and positive clones were identified using a goat antirabbit antibody conjugated to HRP (North East Laboratories). cDNA was isolated from plaque-purified clones (Lockett, 1990) and the excised cDNA inserts were subcloned into pBluescript (Stratagene) or pSPORT 1 (Gibco BRL) for further analysis.

Subcloned cDNA inserts (1 ng) or the cDNA products from reverse transcribing total RNA (5 μg) from cAMP-induced P4 rat Schwann cells using oligo(dT) as primer (Doherty et al., 1989) were amplified by PCR with NF-M-specific primers. Each reaction was subjected to 30 cycles of amplification with 2.5 U AmpliTaq in a total volume of 100 μl of a buffer supplied by the manufacturer (Perkin-Elmer Cetus, Norwalk, CT). The primers used for amplification spanned a 1,234-bp segment of the NF-M sequence between bases 1288 and 2522 using the numbering system of Napolitano et al. (1987).

Restriction endonuclease fragments directionally subcloned into M13 mp8 and mp19 vectors (New England Biolabs, CP Laboratories, Hertfordshire).
the Phagescript vector (Stratagene) were sequenced by the dideoxy chain termination technique (Sanger et al., 1977) using Sequenase (United States Biochemical Corp., Cleveland, OH).

**Results**

E. coli (strain C600) was infected with either λgt11 or a recombinant λgt11 containing a p145 clone pSNP10I1 isolated from the sciatic nerve cDNA library, whose sequence was identical to that of rat NF-M between nucleotides 2137 and 2545, numbered according to Napolitano et al. (1987). The fusion protein was isolated by preparative SDS-gel electrophoresis of E. coli lysates and an antiserum (AI1) was produced in rabbits. Lysates from cells infected with either nonrecombinant λgt11 or recombinant λgt11 containing the pSNP10I1 clone were electrophoretically resolved, transferred to nitrocellulose, and immunblotted with AI1 and affinity-purified anti-p145 at dilutions of 1:1,000 and 1:50, respectively.

**Northern Blot**

Total RNA (5-15 μg) from rat sciatic nerve, cAMP-induced Schwann cells, and brain was electrophoresed on 1.2% formaldehyde agarose gels (Kroczeck and Siebert, 1990) and transferred to Hybond N membrane (Amersham Corp.) by vacuum blotting in 20 x SSC. The filters were probed for 2 h in QuickHyb solution (Stratagene) with a BstEII/DraI fragment of the pSNP10I1 clone that was 3P-labeled by random priming. The autoradiograph shows that the probe recognized a mRNA of ~3 kb in B, SC, and SN thereby supporting the identity of p145 with NF-M.

**Fusion Protein and Antifusion Protein Antibodies**

p145 Is a Schwann Cell Cytoskeleton Protein

Schwann cells were isolated from the sciatic nerves of 5-d-old rat pups and cultured for 24 h in Opti- mem containing 10% FCS. Cells were then extracted with an extraction buffer containing Triton X-100 (Wilson and Brophy, 1989); the resultant cytoskeleton and soluble fractions were electrophoresed on SDS-PAGE and the separated proteins were analyzed by Western blotting. Immunoblotting with affinity-purified anti-p145 and rabbit antivimentin demonstrated that, like vimentin, all of the p145 remains associated with the cytoskeleton fraction and that the anti-p145 specifically recognizes only p145 in Schwann cell cytoskeletons; the vimentin antibody was similarly specific (Fig. 1). The presence of p145 in Schwann cell cytoskeletons was also demonstrated by indirect immunofluorescence (Fig. 2).

p145 Is an IF Protein

The Schwann cell cultures used in some of these experiments also contained fibroblasts. Schwann cells were identified by the phenotype S100+, Thy 1- fibroblasts by the phenotype S100-, Thy 1+, and expressors of p145 were always Thy 1-. The staining pattern of p145 by immunofluorescence in Schwann cells was intracellular and filamentous and was very similar to that observed for vimentin (Fig. 3, B and C). It has long been recognized that when cultured cells are treated with cytoskeleton-disrupting drugs such as colchicine, the classic response of IF proteins is to retract from the cell periphery and reorganize around the nucleus (Yang et al., 1985). This perinuclear bundling of IFs was observed for both p145 and vimentin in response to colchicine treatment (Fig. 3, E and F). When colchicine-treated cultures were allowed to recover in medium without colchicine for a further 24 h, both p145 and vimentin expression reverted to the normal staining pattern (data not shown). The cytoskeleton association and response of p145 to colchicine treatment indicated that this protein may be part of the IF network. Further proof for this hypothesis was provided by immunoelectron microscopy. Schwann cell cytoskeletons were prepared and double labeled with anti-p145 and vimentin mAb followed by gold-conjugated anti-rabbit IgG and anti-mouse IgG secondary antibodies (10 and 5 nm, respectively). The two different sized gold particles decorated the same 10-nm filaments indicating that p145 is a component of IFs and that p145 and vimentin reside on the same IFs (Fig. 4 A). The coexistence of p145 and vimentin is more clearly visible at higher magnification (Fig. 4 B). In addition to containing IFs composed of both p145 and vimentin, some Schwann cells contained only vimentin IFs and these were not labeled with p145 (Fig. 4 C).

**cDNAs from Sciatic Nerve and Schwann Cell Libraries Show p145 Is Identical to NF-M**

We have provided evidence that p145 is an IF protein of Schwann cells; clearly the relationship of this protein to other well-characterized IF proteins is an important question. To establish the identity of p145, a partial cDNA clone, pSNP10I1, was isolated by immune-screening a sciatic nerve cDNA library with anti-p145 and was found to include the sequence between bp 2137-2545 of the rat neurofilament cDNA library. Not only was the pSNP10I1 clone that was 3P-labeled by random priming (Feinberg and Vogelstein, 1983) and they were washed to a final stringency of 0.2 x SSC at 65°C.

**Conclusion**

Schwann cells, isolated from the sciatic nerves of 5-d-old rat pups and cultured for 24 h in Opti- mem containing 10% FCS, were then extracted with an extraction buffer containing Triton X-100 (Wilson and Brophy, 1989); the resultant cytoskeleton and soluble fractions were electrophoresed on SDS-PAGE and the separated proteins were analyzed by Western blotting. Immunoblotting with affinity-purified anti-p145 and rabbit antivimentin demonstrated that, like vimentin, all of the p145 remains associated with the cytoskeleton fraction and that the anti-p145 specifically recognizes only p145 in Schwann cell cytoskeletons; the vimentin antibody was similarly specific (Fig. 1). The presence of p145 in Schwann cell cytoskeletons was also demonstrated by indirect immunofluorescence (Fig. 2).

The Schwann cell cultures used in some of these experiments also contained fibroblasts. Schwann cells were identified by the phenotype S100+, Thy 1- fibroblasts by the phenotype S100-, Thy 1+, and expressors of p145 were always Thy 1-. The staining pattern of p145 by immunofluorescence in Schwann cells was intracellular and filamentous and was very similar to that observed for vimentin (Fig. 3, B and C). It has long been recognized that when cultured cells are treated with cytoskeleton-disrupting drugs such as colchicine, the classic response of IF proteins is to retract from the cell periphery and reorganize around the nucleus (Yang et al., 1985). This perinuclear bundling of IFs was observed for both p145 and vimentin in response to colchicine treatment (Fig. 3, E and F). When colchicine-treated cultures were allowed to recover in medium without colchicine for a further 24 h, both p145 and vimentin expression reverted to the normal staining pattern (data not shown). The cytoskeleton association and response of p145 to colchicine treatment indicated that this protein may be part of the IF network. Further proof for this hypothesis was provided by immunoelectron microscopy. Schwann cell cytoskeletons were prepared and double labeled with anti-p145 and vimentin mAb followed by gold-conjugated anti-rabbit IgG and anti-mouse IgG secondary antibodies (10 and 5 nm, respectively). The two different sized gold particles decorated the same 10-nm filaments indicating that p145 is a component of IFs and that p145 and vimentin reside on the same IFs (Fig. 4 A). The coexistence of p145 and vimentin is more clearly visible at higher magnification (Fig. 4 B). In addition to containing IFs composed of both p145 and vimentin, some Schwann cells contained only vimentin IFs and these were not labeled with p145 (Fig. 4 C).

We have provided evidence that p145 is an IF protein of Schwann cells; clearly the relationship of this protein to other well-characterized IF proteins is an important question. To establish the identity of p145, a partial cDNA clone, pSNP10I1, was isolated by immune-screening a sciatic nerve cDNA library with anti-p145 and was found to include the sequence between bp 2137-2545 of the rat neurofilament protein NF-M cDNA (Napolitano et al., 1987). An antibody (AI1) raised against the β-galactosidase fusion protein product of this clone recognized p145 thus establishing the relationship between p145, pSNP10I1, and NF-M (Fig. 5 a). Western blotting showed that both AI1 and a polyclonal antibody that recognizes the NF triplet NF-L, NF-M, and NF-H cross-reacted with Schwann cell p145 (Fig. 5 b). The absence of NF-L and NF-H from Schwann cells was confirmed by immunofluorescence microscopy (Fig. 6). The NF-M mAb stained Schwann cells in an identical fashion to p145 antibody thus supporting the relatedness of p145 and NF-M (Fig. 6).

Further support for the identity of p145 with NF-M came from Northern blotting in which a mRNA of the same size (~3,000 nucleotides) as that of brain NF-M was detected in sciatic nerve and Schwann cells using pSNP10I1 as probe (Fig. 7).

To establish the precise relationship between p145 and NF-M we prepared a cDNA library from CAMP-induced Schwann cells, screened it with anti-p145 and isolated 24 positive clones. Seven clones were amplified by PCR with primers that span bp 1288-1310 and 2505-2522 of the NF-M.
Figure 8. The complete nucleotide and deduced amino sequence of the Schwann cell NF-M clone pISCP4NFM. Symbols represent points of difference from the sequence of rat brain NF-M (pNF-M2D) as published by Napolitano et al. (1987). Underlined sequences denote additional bases in pSCP4NFM which are not present in pNF-M2D. Single base differences are indicated by the triangles and encircled amino acids denote changes in the amino acid sequence as a result of single base changes. The star between the valine and threonine denotes the position of a codon in brain NF-M that encodes proline which is absent from Schwann cell NF-M. This sequence is available from EMBL/GenBank/DDBJ under accession number Z12152.
Figure 9. Double-label immunofluorescence localization of NF-M with markers of Schwann cell differentiation. Cells were isolated from 1-d rat sciatic nerve and cultured for 16 h. Visualization of NF-M (B, D, and F) was by rhodamine optics and NGFR (A), O4 (C), and GalC (E) by fluorescein optics. All NF-M⁺ cells were NGFR⁺ and O4⁺. In contrast, three phenotypes were detected in E and F: GalC⁺,NF-M⁺ (large arrows); GalC⁺,NF-M⁻ (small arrows); GalC⁻, NF-M⁺ (arrowheads). Bar, 20 μm.
begins in earnest soon after birth (Hahn et al., 1987), we rhodamine optics ((7, F, I) and GalC by fluorescein optics (B, E, H). Cells were also visualized by phase contrast optics (A, D, G). Elevated cell development was investigated by comparing the expression markers: Rand (217c) which is present in most Schwann cells at El8, 04 which appears at El6, and GalC which is first detectable in myelin-forming Schwann cells at E18-19 (Jessen et al., 1990; Mirsky et al., 1990). Since myelination of myelin-forming cells. At P4, 88% of GalC+ cells expressed NF-M which shows that NF-M is expressed by myelin-forming cells.

sequence (Napolitano et al., 1987) and each yielded the predicted 1233-bp fragment, as did direct reverse transcription-PCR amplification of total Schwann cell RNA (data not shown). The longest of these clones, pISCP4E3, was fully sequenced and corresponded to the sequence of NF-M (pNF-M2D) published by Napolitano et al. (1987) from bp 550–2717 together with a further 332 bp at the 3' end to the poly A tail. To complete the sequence at the 5' end an overlapping clone pISCP4B8 of 1693 bp was sequenced. The two overlapping clones constituted pISCP4NFM and contained the entire coding region for NF-M with additional sequence at both the 5' and 3' ends. The full-length clone pISCP4NFM was obtained by ligating the SalI/SacI fragment (5' end) of pISCP4B8 to the SacI/NotI fragment (3' end) of pISCP4E3. The resulting construct was subcloned into pSPORT 1 for further analysis. The relationship between the Schwann cell NF-M and that isolated from brain (Napolitano et al., 1987) is shown in Fig. 8.

Developmental Expression of NF-M in Schwann Cells

The relationship between NF-M expression and Schwann cell development was investigated by comparing the expression of NF-M with that of the well-characterized differentiation markers: Ran-1 (217c) which is present in most Schwann cells at El8, 04 which appears at El6, and GalC which is first detectable in myelin-forming Schwann cells at El8-19 (Jessen et al., 1990; Mirsky et al., 1990). Since myelination begins in earnest soon after birth (Hahn et al., 1987), we considered that cells taken from the sciatic nerves of 1-d-old rat pups should contain a significant number of premylinating and early myelin-forming cells together with a number of non-myelin-forming cells. The cells were cultured for 16 h, and the expression of NGFR, NF-M, O4, and GalC was determined by indirect immunofluorescence. During this period of culture there was no significant dedifferentiation of phenotype as a result of the loss of axonal contact since 31% of the Schwann cells were still strongly P<sub>e</sub> positive.

All of the Schwann cells from 1-d sciatic nerve expressed NGFR whereas much fewer NF-M<sup>e</sup> cells were present (Fig. 9, A and B). Cells that were NGFR<sup>e</sup>, NF-M<sup>e</sup> and NGFR<sup>e</sup>, NF-M<sup>e</sup> were observed but there were no NGFR<sup>e</sup>, NF-M<sup>e</sup> cells which indicated that NGFR expression precedes that of NF-M. Similarly, O4 expression precedes that of NF-M (Fig. 9, C and D). In contrast, cells stained with the O1 mAb which specifically recognizes GalC displayed three phenotypes: GalC<sup>e</sup>, NF-M<sup>e</sup>, GalC<sup>e</sup>, NF-M<sup>e</sup>, and a relatively small number of GalC<sup>e</sup>, NF-M<sup>e</sup> (Fig. 9, E and F). These results suggested that NF-M appears during Schwann cell development in the rat sciatic nerve after O4 but somewhat earlier than GalC.

To elucidate the time of NF-M appearance during development, and the relationship between NF-M expression and myelination, Schwann cells were isolated from sciatic nerves at El8, and from nerves at P1 and P4. After 16 h in culture, the cells were double labeled for NF-M and GalC and for NF-M and O4 (Fig. 10). The percentage of cells in these cultures that were Schwann cells was determined by measuring the number of S100<sup>e</sup> cells in parallel cultures (87 ± 1% at El8, 86 ± 2% at P1, and 72 ± 2% at P4). At each age, cells had been in culture for 16 h before processing for indirect immunofluorescence. O4 expression, which is first detected in Schwann cells at El6, increased from 69% of Schwann cells on El8 to 96% of Schwann cells on P4 (Fig. 10). This trend was consistent with the increased expression on Schwann cells of O4 with age observed by Jessen and Mirsky (1991). The number of Schwann cells expressing NF-M also showed an increase with age from 29% on El8 to 58% on P4. Our results on GalC expression are difficult to compare with others' work as we used the O1 antibody which is more specific for GalC (Bansal et al., 1990) than is the R-mAb antibody used in other studies (Mirsky et al., 1990). The percentage of Schwann cells expressing GalC increased from 9% on El8, through 14% on P1 to 36% on P4. At P4, three GalC, NF-M phenotypes were observed: GalC<sup>e</sup>, NF-M<sup>e</sup> (50 ± 3%), GalC<sup>e</sup>, NF-M<sup>e</sup> (7 ± 2%), and GalC<sup>e</sup>, NF-M<sup>e</sup> (43 ± 4%). Thus, 88% of the GalC<sup>e</sup> cells expressed NF-M, which indicates that NF-M is present in myelin-forming Schwann cells. Myelin synthesis begins in earnest on P1 and we found the expected rise in P<sub>e</sub> expression by Schwann cells from 31% on P1 to 56% on P4. Our values for the observed expression of P<sub>e</sub> on P1 and P4 paralleled those for NF-M and support our argument that NF-M is a component of myelin-forming Schwann cells.

Figure 10. Histogram showing the percentage of Schwann cells expressing O4, GalC, and NF-M at ages El8, P1, and P4. Schwann cells were isolated from sciatic nerves and kept in culture for 16 h before processing for indirect immunofluorescence. The number of Schwann cells as determined by S100 immunoreactivity was: 87 ± 1% at El8, 86 ± 2% at P1, and 72 ± 2% at P4. The increase in the number of GalC<sup>e</sup> cells from El8 to P4 reflects the differentiation of myelin-forming cells. At P4, 88% of GalC<sup>e</sup> cells expressed NF-M which shows that NF-M is expressed by myelin-forming cells.

Figure 11. Double-label immunofluorescence showing the induction by cAMP analogues of NF-M and GalC in Schwann cells. Schwann cells were isolated from 5-d rat sciatic nerves and cultured for 24 h in OptiMem and 10% FCS. They were then cultured for a further 48 h in: (A–C) 10% FCS, (D–F) 10% FCS and 10 μM db-cAMP; (G–I), 10 μM db-cAMP without FCS. The NF-M was visualized by rhodamine optics (C, F, I) and GalC by fluorescein optics (B, E, H). Cells were also visualized by phase contrast optics (A, D, G). Elevated cAMP induces NF-M (F and I) but GalC expression also requires serum deprivation (H). Bar, 20 μm.
Figure 12. Indirect immunofluorescence of NF-M and P0 in Schwann cells after treatment with db-cAMP. Schwann cells from 5-d rat sciatic nerve were treated with cAMP analogues for 3 d as in Materials and Methods. Cultures were viewed with rhodamine optics to visualize NF-M and fluorescein optics to visualize P0. Bar, 10 μm.

**Induction of NF-M in Schwann Cells by cAMP Analogues**

Schwann cells were isolated from sciatic nerves of rats at P5 and grown in Optimem 1 containing 10% FCS for 24 h before treatments with db-cAMP. When cells were kept for a further 48 h in Optimem containing 10% FCS, they dedifferentiated and very few cells expressed NF-M or were stained with R-mAb which recognizes GalC and the O4 antigen (Fig. 11, B and C). However, if after the initial 24 h of culture cells were kept for 48 h in Optimem containing 10% FCS and db-cAMP, the loss of expression of NF-M was prevented (Fig. 11 F) which suggests that NF-M expression in Schwann cells is under axonal regulation because elevation of intracellular cAMP levels is believed to mimic the effects of axons on Schwann cells (Sobue and Pleasure, 1984a, 1986; Porter et al., 1986).

The change in Schwann cell morphology induced by db-cAMP (Fig. 11 E) is well documented (Sobue et al., 1986; Morgan et al., 1991). If serum were removed after the initial 24 h in Optimem and 10% FCS, and the cells were kept for a further 48 h in Optimem with db-cAMP, expression of NF-M was induced (Fig. 11 I) and all of the NF-M+ cells were R-mAb+ (Fig. 11 H). P0 induction can only be induced by cAMP analogues when Schwann cells are quiescent (Morgan et al., 1991), and Fig. 12 shows that these P0+ cells are also NF-M+. Thus, NF-M is present in cells expressing myelin proteins. In parallel experiments designed to map the appearance of NF-M expression during Schwann cell development, we found that O4 and NF-M appear in dividing cells and precede the appearance of GalC and P0 (Figs. 9 and 10) both of which are only expressed in nondividing cells (Morgan et al., 1991). Thus, the results from tissue culture studies were consistent with development in vivo.

Cultured Schwann cells were metabolically labeled in the presence of db-cAMP, and anti-p145 specifically immunoprecipitated a protein of Mr 145 (Fig. 13, lane 3). In all three lanes, vimentin and some bands with lower Mr were precipitated, even when an irrelevant antibody was used (Fig. 13, lane 1). Antivimentin did not immunoprecipitate NF-M (Fig. 13, lane 2) which is consistent with our finding that this antibody does not recognize NF-M on a Western blot, nor does the anti-p145 recognize vimentin (Fig. 1). The NF-M could not be immunoprecipitated from dedifferentiated cells (data not shown) which supports our contention that NF-M is a protein of differentiating Schwann cells.

**Discussion**

In this paper we have described a component of the IF network of differentiating Schwann cells which we initially called p145 and subsequently identified as NF-M. We have identified p145 as an IF protein because it is exclusively present in the cytoskeleton, it bundles perinuclearly in response to colchicine, and because it can be detected by immunoelectron microscopy in IFs. Axonal contact appears to regulate NF-M expression because it is lost from dissociated Schwann cells in tissue culture and because cAMP, which is believed to mimic some of the effects of axons on Schwann cells, induces re-expression of the protein.
In the rat sciatic nerve, the first Schwann cells appear at E15-16 (Jessen and Mirsy, 1991); in response to axon-Schwann cell contact they begin to express O4 between E16 and E17 and by E20 all Schwann cells express O4 (Jessen et al., 1990). Consistent with these earlier data we found a high number of O4⁺ cells in our cultures from sciatic nerves at E18 (69%), and by P4 essentially all Schwann cells expressed this marker. Myelinating-forming cells express GalC at E18-19 whereas non-myelinating Schwann cells differentiate later. We found an increase in the percentage of Schwann cells expressing GalC from 9% on E18 to 36% on P4, a result which is consistent with the increase in abundance of cells expressing the myelin protein P, during this period (31% on P1 and 56% on P4). The percentage of cells which expressed P, on P1 and P4 was greater than that which expressed GalC, indicating that P, expression precedes that of surface GalC. The fact that 88% of the GalC⁺ cells also expressed NF-M clearly demonstrated that NF-M is a protein of myelinating Schwann cells. Furthermore, we observed that NF-M was retained in Schwann cells that were induced to re-express P, (Fig. 12). Further work will be needed in order to delineate the expression of NF-M in non-myelinating cells.

The two IF proteins of Schwann cells that have been described so far are vimentin and GFAP. Vimentin is present in both differentiated and undifferentiated Schwann cells (Autilio-Gambetti et al., 1982) and can be detected in Schwann cell cultures from E15 onwards (Jessen et al., 1990). GFAP is first detected on E18 but down-regulates as the myelinating phenotype develops (Jessen et al., 1990). Therefore, we considered the possibility that NF-M replaced GFAP in myelinating Schwann cells. We were able to detect GFAP in a small number of Schwann cells at P4 (5%) using the G-A-5 mAb. A much larger number was detectable with a polyclonal anti-GFAP from Dakopatts (38%), which is consistent with the data of Jessen et al. (1990). However, immunoblotting experiments revealed that the Dakopatts antibody was not specific for GFAP, and that it cross-reacted with NF-M, a result that is consistent with the findings of Hansen et al. (1989) who found that this antibody recognizes neurofilaments. When G-A-5 was used, no difference in GFAP immunoreactivity was observed in cultures from 1- and 4-old sciatic nerves. Therefore, we suggest that NF-M and vimentin are the main IF proteins of differentiating Schwann cells. There are several precedents for the exchange of IF protein networks during cell differentiation and NF-M may replace GFAP at a very early stage of Schwann cell development in the sciatic nerve (Lazarides, 1982; Cossette and Vincent, 1991; Lendahl et al., 1990; Fliegl et al., 1990; Steinert and Liem, 1990). Myelination necessitates major changes in Schwann cell morphology which must involve the cytoskeleton and the NF-M IF protein may be best suited to the role of sustaining the altered shape which allows axon ensheathment and subsequent myelination.

This paper is the first report of the normal occurrence of an IF protein of the NF type in nonneuronal cells in the nervous system. Although NF proteins are normally restricted to postmitotic neurons, NF-L has been detected in the beta cells of the islets of Langerhans in the embryonic rat, thus raising the possibility that these cells originate in the neural crest (Escurat et al., 1991). Furthermore, NF proteins have been incorporated into IF-like arrays in nonneuronal cells after transfection (Monteiro and Cleveland, 1990; Chin and Liem, 1990) and in transgenic mice (Monteiro et al., 1990). It has not escaped our attention that the abundance of NFs in peripheral nerves makes the detection of NF-like proteins in Schwann cells in vivo a difficult task which probably explains why Schwann cell NF-M has been overlooked until now. It should be emphasized however that mRNA encoding NF-M was detected by Northern blotting in sciatic nerve (Fig. 7). Why differentiating Schwann cells should synthesize a NF-like protein remains unclear. Equally puzzling is why Schwann cells synthesize NF-M alone of the NF triplet since these proteins are normally coordinately expressed in neurons. At any rate, the possibility that NF-like proteins exist in other nonneuronal cells should now be considered seriously.

We wish to thank Mr. Demetrius Vouyioukis for editorial help and Mr. Lewis Taylor for photographic assistance.

This work was supported by the Multiple Sclerosis Society of Great Britain in Scotland.

Received for publication 8 October 1991 and in revised form 28 February 1992.

References

Autilio-Gambetti, L. J. Sipple, O. Sudilovsky, and P. Gambetti. 1982. Intermediate filaments of Schwann cells. J. Neurochem. 38:774-780.
Aviv, H., and P. Leder. 1972. Purification of biologically active globin messenger RNA by chromatography on oligo(dT)-cellulose. Proc. Natl. Acad. Sci. USA. 69:1408-1412.
Bansal, R., A. E. Warrington, A. L. Gard, and S. E. Pfeiffer. 1989. Multiple and novel specificities of monoclonal antibodies 01, 04 and R-mAb used in the analysis of oligodendrocyte development. J. Neurosci. Res. 24:548-557.
Bansal, R., A. E. Warrington, A. L. Gard, B. Ranacht, and S. E. Pfeiffer. 1990. Characterization of monoclonal antibodies 01, 04 and R-mAb used in the analysis of oligodendrocyte development. Annu. N. Y. Acad. Sci. 505:409-411.
Brookes, J. P., K. L. Fields, and M. C. Raff. 1979. Studies on cultured rat Schwann cells. 1. Establishment of purified populations from cultures of peripheral nerve. Brain Res. 165:105-118.
Brunden, K. R., A. J. Windebank, and J. F. Poduslo. 1990. Role of axons in the regulation of P, biosynthesis by Schwann cells. J. Neurosci. Res. 26:135-143.
Bunge, R. P., M. B. Bunge, and C. F. Eldridge. 1986. Linkage between axonal ensheathment and basal lamina production by Schwann cells. Annu. Rev. Neurosci. 9:305-328.
Chin, S. S. M., and R. K. H. Liem. 1989. Expression of rat neurofilament protein proteins NF-L and NF-M in transfected non-neural cells. Eur. J. Cell Biol. 50:475-490.
Chin, S. S. M., and R. K. H. Liem. 1990. Transfected rat High-molecular-weight neurofilament (NF-H) coassembles with vimentin in a predominantly nonphosphorylated form. J. Neurosci. 10:3714-3726.
Chin, S. S. M., P. Macioce, and R. K. H. Liem. 1991. Effects of truncated neurofilaments on the endogenous intermediate filaments in transfected fibroblasts. J. Cell Sci. 99:335-350.
Cossette, L. J., and M. Vincent. 1991. Expression of a developmentally regulated cross-linking intermediate filament-assoiated protein (IF/Apo-400) during the replacement of vimentin for desmin in muscle cell differentiation. J. Cell Sci. 98:251-260.
DeVries, G. H., J. L. Satzer, and R. P. Bunge. 1982. Axolemma-enriched fractions isolated from CNS and CNS are mitogenic for cultured Schwann cells. Dev. Brain Res. 3:295-299.
Eccleston, P. A., R. Mirsky, K. R. Jessen, I. Sommer, and M. Schachner. 1987. Postnatal development of rat peripheral nerves: an immunohistochemical study of membrane lipids common to non-myelinating Schwann cells and oligodendrocytes. Dev. Brain Res. 35:249-256.
Escurat, M., K. Djebali, C. Hue, F. Landon, C. Bécourt, C. Boitard, F. Gros, and M.-M. Portier. 1991. Origin of the beta cells of the islets of Langerhans is further questioned by the expression of neuronal intermediate filament proteins, peripherin and NF-L, in the rat insulinoma RINSF cell line. Dev. Neurosci. 13:424-432.
Feinberg, A. P., and B. Vogelstein. 1983. A technique for radio labelling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 132:6-13.
Fliegl, K. H., G. Y. Ching, and R. K. H. Liem. 1990. The predicted amino acid sequence of α-internexin is that of a novel neuronal intermediate filament protein. EMBO (Eur. Mol. Biol. Organ.) J. 9:749-755.
Geiger, B. 1987. Intermediate filaments. Looking for a function. Nature (Lond.). 329:392-393.
Georgatos, S. D., K. Weber, N. Geisler, and G. Blobel. 1987. Binding of two desmin derivatives to the plasma membrane and the nuclear envelope of avian erythrocytes: evidence for a conserved site-specificity in intermediate filament-membrane interactions. *Proc. Natl. Acad. Sci. USA.* 84:6780-6784.

Goldman, R., A. Goldman, K. Green, J. Jones, N. Lieszka, and H. Y. Yang. 1985. Intermediate filaments: possible functions as cytoskeletal connecting links between the nucleus and the cell surface. *Ann. NY Acad. Sci.* 455:1-17.

Gubler, U., and B. J. Hoffman. 1983. A simple and very efficient method for generating cDNA libraries. *Gene.* 25:263-269.

Hahn, A. F., J. N. Whitaker, B. Kachar, and H. deF. Webster. 1987. P, and P. Myelin protein expression in developing rat sixth nerve: a quantitative immunocytochemical study. *J. Comp. Neurol.* 260:501-512.

Hansen, S. H., M. Staggaard, and K. Møllgård. 1989. Neurofilament-like pattern of reactivity in human fetal PNS and spinal cord following immunostaining with polyclonal anti-glia fibrillary acidic protein antibodies. *J. Neurocytol.* 18:427-436.

Henkoff, S. 1984. Unidirectional digestion with Exonuclease III creates targeted breakpoints for DNA sequencing. *Gene.* 28:351-359.

Hoffman, P. N., J. W. Griffin, and D. L. Price. 1984. Control of axonal caliber by neurofilament transport. *J. Cell Biol.* 99:705-714.

Hunkapiller, M. W., E. U. Lujan, F. Ostrander, and L. E. Hood. 1984. Isolation of microgram quantities of proteins from polyacrylamide gels for amino acid sequence analysis. *Methods Enzymol.* 91:227-236.

Jessen, K. R., and R. Mirsky. 1985. Gial fibrillary acidic polypeptides in peripheral glia: Molecular weight, heterogeneity and distribution. *J. Neuroimmunol.* 8:377-393.

Jessen, K. R., and R. Mirsky. 1991. Schwann cell precursors and their development. *Glia.* 4:185-194.

Jessen, K. R., R. Mirsky, and L. Morgan. 1987. Axonal signals regulate the differentiation of non-myelin forming Schwann cells: an immunohistochecmical study of galactocerebroside in transected and regenerating nerves. *J. Neurosci.* 7:3526-3539.

Jessen, K. R., L. Morgan, H. J. S. Stewart, and R. Mirsky. 1990. Three markers of adult non-myelin-forming Schwann cells, 217e (Ran-1), A5E2 and GFAP: development and regulation by neuron-Schwann cell interactions. *Development (Camb.)* 109:91-103.

Kroczyk, R. A., and E. Siebert. 1990. Optimization of northern analysis by vacuum-blotting, RNA-transfer visualization and ultraviolet fixation. *Anal. Biochem.* 184:90-95.

Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature (Lond.)* 227:680-685.

Lazaridis, E. 1982. Intermediate filaments: a chemically heterogeneous, developmentally regulated class of proteins. *Annu. Rev. Biochem.* 51:219-250.

Lemke, G., and M. Chao. 1988. Axons regulate Schwann cell expression of the major myelin and NGF receptor genes. *Development (Camb.)* 102:499-504.

Lendahl, U., L. B. Zimmerman, and R. D. G. McKay. 1990. CNS stem cells express a new class of intermediate filament protein. *Cell.* 60:585-595.

Lockett, T. J. 1990. A bacteriophage ADNA purification procedure suitable for the analysis of DNA from either large or multiple small lysates. *Anal. Biochem.* 185:230-234.

Mirska, R., J. Wintzer, E. R. Abney, R. M. Pruss, J. Gavrilovic, and M. C. Raff. 1980. Myelin-specific proteins and glycolipids in rat Schwann cells and oligodendrocytes in culture. *J. Cell Biol.* 84:453-464.

Mirsky, R., C. Dubois, L. Morgan, and K. R. Jessen. 1990. O4 and A007-sulfatide antibodies bind to embryonic Schwann cells prior to the appearance of galactocerebroside: regulation of the antigen by axon-Schwann cell signals and cyclic AMP. *Development (Camb.)* 109:105-116.

Monteiro, M. J., and D. W. Cleveland. 1989. Expression of NF-L and NF-M in fibroblasts reveals coassembly of neurofilament and vimentin subunits. *J. Cell Biol.* 108:579-593.

Monteiro, M. J., P. N. Hoffman, J. D. Gearhart, and D. W. Cleveland. 1990. Expression of NF-L in both neural and nonneural cells of transgenic mice: increased neurofilament density in axons without affecting caliber. *J. Cell Biol.* 111:1543-1557.

Morgan, L., K. R. Jessen, and R. Mirsky. 1991. The effects of cAMP on differentiation of cultured Schwann cells: progression from an early phenotype (O4) to a myelin phenotype (P0, GFAP, NCAM, NGF receptor) depends on growth inhibition. *J. Cell Biol.* 112:457-467.

Napolitano, E. W., S. S. M. Chin, D. R. Colman, and R. K. H. Liem. 1987. Complete amino acid sequence and in vitro expression of rat NF-M, the middle molecular weight neurofilament protein. *J. Neurosci.* 7:2590-2599.

Noble, M. S., S. Barnett, O. Bögl, H. Land, G. Wolsikjik, and D. Wren. 1990. Protooncogenes in cell development. *Ciba Found. Symp.* 150:227-249.

Osborn, M., and K. Weber. 1983. Biology of disease. Tumour diagnosis by intermediate filament typing: a novel tool for surgical pathology. *Lab Invest.* 48:3372-3394.

Porter, S., M. B. Clark, L. Glaser, and R. P. Bunge. 1986. Schwann cells stimulated to proliferate in the absence of neurons retain full functional capacity. *J. Neurosci.* 6:3070-3078.

Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA.* 74:5463-5467.

Salzer, J. J., and R. P. Bunge. 1980. Studies of Schwann cell proliferation I. An analysis in tissue culture of proliferation during development, Wallerian degeneration and direct injury. *J. Cell Biol.* 84:739-752.

Sobue, G., and D. Pleasure. 1984. Schwann cell galactocerebroside induced by derivatives of adenosine 3'-5' monophosphate. *Science (Wash. DC).* 224:72-74.

Sobue, G., and D. Pleasure. 1985. Adhesion of axonemal fragments to Schwann cells. A signal- and target-specific process closely linked to axonemal induction. *J. Neurosci.* 5:379-387.

Sobue, G., S. Shuman, and D. Pleasure. 1986. Schwann cell responses to cyclic AMP: proliferation, change in shape, and appearance of surface galactocerebroside. *Brain Res.* 362:23-32.

Sommer, L., and M. Schachner. 1981. Monoclonal antibodies (01 to 04) to oligodendrocyte cell surfaces: an immunocytochemical study in the central nervous system. *Dev. Biol.* 83:311-327.

Steinert, P. M., and R. K. H. Liem. 1990. Intermediate Filament Dynamics. *Cold Spring Harbor Symp. Quant. Biol.* 48:717-729.

Weinstein, D. E., M. I. Shelanski, and R. K. H. Liem. 1991. Suppression by antisense mRNA demonstrates a requirement for the gial fibrillary acidic protein in the formation of stable astrocytic processes in response to neurons. *J. Cell Biol.* 112:1205-1213.

Wilson, R., and P. J. Brophy. 1989. Role for the oligodendrocyte cytokine in myelination. *J. Neurosci.* 22:439-448.

Yan, Q., and E. M. Johnson. 1988. An immunohistochemical study of nerve growth factor receptors in developing rats. *J. Neurosci.* 8:3481-3498.

Young, R. A., and R. W. Davis. 1983. Efficient isolation of genes by using antibody probes. *Proc. Natl. Acad. Sci. USA.* 80:1194-1198.